CLDN5 and myeloid sarcoma: Claudin-5 expression was downregulated in immortalized human brain microvascular endothelial cells (TY09) after treatment with sera from the relapse phase of relapse-remitting MS (RRMS-R) or secondary progressive MS (SPMS) (127).